How I Treat丨Prof. Fengkui Zhang: My Approach to Treating Severe Aplastic Anemia

How I Treat丨Prof. Fengkui Zhang: My Approach to Treating Severe Aplastic Anemia

Severe aplastic anemia (AA) remains a significant therapeutic challenge despite progress in its diagnosis and treatment. Issues such as difficulty in donor matching, side effects of immunosuppressive therapy (IST), and suboptimal hematologic responses demand continued exploration of innovative solutions. Prof. Fengkui Zhang of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences delivered a compelling presentation on treating severe aplastic anemia. In an interview with Hematology Frontier, Prof. Zhang shared insights into managing refractory aplastic anemia and the latest treatment advancements.
SIBCS 2024 | A Sneak Peek at Key Updates in the 2025 Edition of the “CBCS Little Red Book” from Top Experts

SIBCS 2024 | A Sneak Peek at Key Updates in the 2025 Edition of the “CBCS Little Red Book” from Top Experts

The expert voting on key issues for the 2025 edition of the Guidelines and Standards for Breast Cancer Diagnosis and Treatment (Essential Version), also known as the CBCS Little Red Book, organized by the Chinese Anti-Cancer Association and the Chinese Medical Association’s Oncology Branch, has concluded. The new version is on the horizon! Oncology Frontier interviewed several prominent members of the advisory board who participated in the voting, including Prof. Yiding Chen, Prof. Hengyu Li, Prof. Man Li, Prof. Shu Liu, Prof. Yongsheng Wang, and Prof. Jian Zhang, to provide insights into the potential updates in the 2025 edition.
Dr. Yige Bao: Perioperative Personalized Treatment of UTUC Based on ADC Drugs and the West China Experience

Dr. Yige Bao: Perioperative Personalized Treatment of UTUC Based on ADC Drugs and the West China Experience

Upper tract urothelial carcinoma (UTUC), encompassing renal pelvic and ureteral cancers, is relatively rare, with unique characteristics in the Chinese population, such as distinct disease features and molecular biology profiles. The 8th West China Uro-Oncology Tianfu Academic Conference, recently held in Chengdu, provided a platform to discuss how to better address the challenges in UTUC treatment and improve patient outcomes. In this event, Oncology Frontier interviewed Dr. Yige Bao from West China Hospital of Sichuan University, who shared insights into personalized perioperative treatment of UTUC with ADC drugs and the hospital's clinical experiences.
2024 WAAW丨Dr. Pengfei Shen: Why Urinary Tract Infections Trouble Women？

2024 WAAW丨Dr. Pengfei Shen: Why Urinary Tract Infections Trouble Women？

The third week of every November marks World Antimicrobial Awareness Week (WAAW). This year, WAAW adopts the theme: "Educate, Advocate, Act," aiming to raise public awareness about antimicrobial drugs, advocate for their appropriate use, and encourage action to combat antimicrobial resistance (AMR). In response to this call, Oncology Frontier invited Dr. Pengfei Shen from West China Hospital of Sichuan University to provide an informative overview of female urinary tract infections (UTIs), exploring why women are more prone to these infections, common symptoms, frequently used antibiotics, and the importance of responsible medication use to prevent antibiotic resistance.
CCHIO 2024丨Dr. Qingbo Wang: Comprehensive Treatment Strategies for Tuberculosis-Associated Lung Cancer

CCHIO 2024丨Dr. Qingbo Wang: Comprehensive Treatment Strategies for Tuberculosis-Associated Lung Cancer

At the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO), during the Infectious Tumors Subcommittee session, Dr. Qingbo Wang from The Second Hospital of Nanjing presented a report titled "Comprehensive Treatment Strategies for Tuberculosis-Associated Lung Cancer." The presentation explored the epidemiology, diagnostic challenges, and treatment strategies for patients with coexisting tuberculosis (TB) and lung cancer.
CCHIO 2024丨Dr. Ming Zhao: Exploring Combined Local and Systemic Therapies for Intermediate and Advanced Liver Cancer—Foundations, Current Status, and Future Prospects

CCHIO 2024丨Dr. Ming Zhao: Exploring Combined Local and Systemic Therapies for Intermediate and Advanced Liver Cancer—Foundations, Current Status, and Future Prospects

With advancements in local treatment techniques and the emergence of new therapeutic agents, combined local and systemic therapies have demonstrated synergistic effects greater than the sum of their parts in liver cancer management. For patients with intermediate and advanced liver cancer, this approach has improved conversion therapy success rates and even achieved curative outcomes. At the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO), during the "Interventional Oncology" session, Dr. Ming Zhao from the Sun Yat-sen University Cancer Center shared his insights on the combined treatment approach. Oncology Frontier interviewed Professor Zhao to discuss the theoretical foundations, current developments, and future directions of combined local and systemic therapies.
CCHIO 2024丨Academician Daiming Fan: Integrative Medicine Ushers in a New Era of Cancer Prevention and Treatment

CCHIO 2024丨Academician Daiming Fan: Integrative Medicine Ushers in a New Era of Cancer Prevention and Treatment

The 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) opened grandly in the ancient city of Xi’an on November 16, focusing on the theme "Winning Against Cancer Through Integration." This conference brought together global medical elites to strategize for global health solutions. During the event, conference chair and President of the China Anti-Cancer Association (CACA), Academician Daiming Fan, shared insights in an interview with Oncology Frontier. He delved into the pivotal role of integrative medicine in advancing global medical progress and its profound impact on the future of healthcare.